Now online in JCO #postMonarch
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial ascopubs.org/doi/pdf/10.1... @oncoalert.bsky.social #oncsky
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial ascopubs.org/doi/pdf/10.1... @oncoalert.bsky.social #oncsky
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial
PURPOSECyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET)
are the standard first-line treatment for hormone receptor-positive (HR+), human epidermal
growth factor re...
ascopubs.org
December 22, 2024 at 10:31 PM
Now online in JCO #postMonarch
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial ascopubs.org/doi/pdf/10.1... @oncoalert.bsky.social #oncsky
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial ascopubs.org/doi/pdf/10.1... @oncoalert.bsky.social #oncsky
New JCO 📰 #Abemaciclib Plus #Fulvestrant in Advanced #BreastCancer Following Progression on CDK4/6 Inhibition: Results from the postMONARCH Trial
🔓https://pubmed.ncbi.nlm.nih.gov/39693591/
✍️ @erikahamilton9.bsky.social @drsgraff.bsky.social @drsarahsammons.bsky.social @bastien-nguyen.bsky.social
🔓https://pubmed.ncbi.nlm.nih.gov/39693591/
✍️ @erikahamilton9.bsky.social @drsgraff.bsky.social @drsarahsammons.bsky.social @bastien-nguyen.bsky.social
January 17, 2025 at 4:33 PM
New JCO 📰 #Abemaciclib Plus #Fulvestrant in Advanced #BreastCancer Following Progression on CDK4/6 Inhibition: Results from the postMONARCH Trial
🔓https://pubmed.ncbi.nlm.nih.gov/39693591/
✍️ @erikahamilton9.bsky.social @drsgraff.bsky.social @drsarahsammons.bsky.social @bastien-nguyen.bsky.social
🔓https://pubmed.ncbi.nlm.nih.gov/39693591/
✍️ @erikahamilton9.bsky.social @drsgraff.bsky.social @drsarahsammons.bsky.social @bastien-nguyen.bsky.social
16/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
🔙 to our case
EMBER3 would be a great option, but based on availability, pt got elacestrant
🚫 abema+fulvestrant:
-ESR1 Y537S 👉fulvestrant resistance.
-POSTMONARCH👉modest PFS benof abema+fulv vs placebo+fulv AND 🚫benefit in subgroup w/ prior ribo
🔙 to our case
EMBER3 would be a great option, but based on availability, pt got elacestrant
🚫 abema+fulvestrant:
-ESR1 Y537S 👉fulvestrant resistance.
-POSTMONARCH👉modest PFS benof abema+fulv vs placebo+fulv AND 🚫benefit in subgroup w/ prior ribo
January 15, 2025 at 1:45 AM
16/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
🔙 to our case
EMBER3 would be a great option, but based on availability, pt got elacestrant
🚫 abema+fulvestrant:
-ESR1 Y537S 👉fulvestrant resistance.
-POSTMONARCH👉modest PFS benof abema+fulv vs placebo+fulv AND 🚫benefit in subgroup w/ prior ribo
🔙 to our case
EMBER3 would be a great option, but based on availability, pt got elacestrant
🚫 abema+fulvestrant:
-ESR1 Y537S 👉fulvestrant resistance.
-POSTMONARCH👉modest PFS benof abema+fulv vs placebo+fulv AND 🚫benefit in subgroup w/ prior ribo
The postMONARCH Phase III trial reported new data for HR+/HER2- advanced breast cancer patients progressing on prior CDK4/6 inhibitors (CDK4/6i).
🔬 Key Findings 👇
@ascocancer.bsky.social @ascopost.bsky.social @conquercancer.bsky.social
#Onco404 #Cancer #BreastCancer #Oncology #JCO #ASCO
🔬 Key Findings 👇
@ascocancer.bsky.social @ascopost.bsky.social @conquercancer.bsky.social
#Onco404 #Cancer #BreastCancer #Oncology #JCO #ASCO
March 20, 2025 at 8:56 AM
The postMONARCH Phase III trial reported new data for HR+/HER2- advanced breast cancer patients progressing on prior CDK4/6 inhibitors (CDK4/6i).
🔬 Key Findings 👇
@ascocancer.bsky.social @ascopost.bsky.social @conquercancer.bsky.social
#Onco404 #Cancer #BreastCancer #Oncology #JCO #ASCO
🔬 Key Findings 👇
@ascocancer.bsky.social @ascopost.bsky.social @conquercancer.bsky.social
#Onco404 #Cancer #BreastCancer #Oncology #JCO #ASCO
postMONARCH ctDNA Analysis Underscores Benefit of Abemaciclib Plus Fulvestrant in HR+ Advanced Breast Cancer @myesmo.bsky.social #ESMOBreast25 #bcsm #oncology
www.onclive.com/view/postmon...
www.onclive.com/view/postmon...
www.onclive.com
May 19, 2025 at 7:53 PM
postMONARCH ctDNA Analysis Underscores Benefit of Abemaciclib Plus Fulvestrant in HR+ Advanced Breast Cancer @myesmo.bsky.social #ESMOBreast25 #bcsm #oncology
www.onclive.com/view/postmon...
www.onclive.com/view/postmon...
New postMONARCH data show abemaciclib + fulvestrant improves outcomes in HR+/HER2– mBC after CDK4/6i failure—benefit seen across key biomarker subgroups. docwirenews.com/post/postmon... #ESMOBreast25 #bcsm
@myesmo.bsky.social
@myesmo.bsky.social
PostMONARCH: Abemaciclib Combo Effective After CDK4/6i Failure | Docwire News
Abemaciclib plus fulvestrant showed benefit across biomarkers after CDK4/6i failure in advanced HR+/HER2- breast cancer.
docwirenews.com
May 16, 2025 at 7:29 PM
New postMONARCH data show abemaciclib + fulvestrant improves outcomes in HR+/HER2– mBC after CDK4/6i failure—benefit seen across key biomarker subgroups. docwirenews.com/post/postmon... #ESMOBreast25 #bcsm
@myesmo.bsky.social
@myesmo.bsky.social